Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2022 | 309 | 3.200 |
Why?
|
| Myocardial Infarction | 9 | 2025 | 226 | 3.060 |
Why?
|
| Heart Failure | 7 | 2026 | 414 | 2.640 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2025 | 168 | 1.640 |
Why?
|
| Hospitalization | 7 | 2025 | 831 | 1.550 |
Why?
|
| Medication Adherence | 5 | 2024 | 232 | 1.530 |
Why?
|
| Stroke Volume | 3 | 2024 | 109 | 1.500 |
Why?
|
| Cholesterol, LDL | 4 | 2025 | 117 | 1.360 |
Why?
|
| African Americans | 5 | 2020 | 429 | 1.240 |
Why?
|
| Cardiovascular Diseases | 4 | 2026 | 545 | 1.170 |
Why?
|
| Proprotein Convertase 9 | 2 | 2019 | 2 | 1.150 |
Why?
|
| Hypertension | 6 | 2026 | 486 | 1.140 |
Why?
|
| Male | 26 | 2026 | 10014 | 1.060 |
Why?
|
| Female | 26 | 2026 | 12715 | 0.950 |
Why?
|
| Humans | 31 | 2026 | 17622 | 0.950 |
Why?
|
| Hypercholesterolemia | 1 | 2025 | 25 | 0.920 |
Why?
|
| Middle Aged | 18 | 2026 | 7954 | 0.910 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 120 | 0.910 |
Why?
|
| Safety-net Providers | 1 | 2025 | 55 | 0.890 |
Why?
|
| Physicians, Primary Care | 1 | 2025 | 63 | 0.870 |
Why?
|
| Aged | 21 | 2026 | 6223 | 0.860 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 204 | 0.820 |
Why?
|
| Natural Language Processing | 1 | 2024 | 60 | 0.800 |
Why?
|
| Patient Compliance | 1 | 2025 | 269 | 0.800 |
Why?
|
| United States | 15 | 2026 | 3922 | 0.750 |
Why?
|
| Politics | 1 | 2020 | 10 | 0.660 |
Why?
|
| Incidence | 8 | 2026 | 1278 | 0.650 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 208 | 0.630 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 689 | 0.620 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 4 | 0.610 |
Why?
|
| Lipoprotein(a) | 1 | 2019 | 5 | 0.610 |
Why?
|
| Adult | 12 | 2026 | 7621 | 0.600 |
Why?
|
| Stress, Psychological | 1 | 2020 | 141 | 0.590 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 55 | 0.580 |
Why?
|
| Perception | 1 | 2019 | 56 | 0.580 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 45 | 0.570 |
Why?
|
| Forecasting | 1 | 2019 | 68 | 0.570 |
Why?
|
| Self Report | 2 | 2017 | 262 | 0.560 |
Why?
|
| Retrospective Studies | 12 | 2026 | 2502 | 0.560 |
Why?
|
| Cognition Disorders | 1 | 2017 | 31 | 0.530 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 540 | 0.520 |
Why?
|
| Genetic Variation | 1 | 2017 | 82 | 0.520 |
Why?
|
| Cognition | 1 | 2017 | 91 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 187 | 0.500 |
Why?
|
| Risk Factors | 9 | 2025 | 3291 | 0.500 |
Why?
|
| Aged, 80 and over | 8 | 2026 | 1976 | 0.490 |
Why?
|
| Insurance Coverage | 1 | 2017 | 99 | 0.480 |
Why?
|
| Ethnic Groups | 1 | 2019 | 443 | 0.470 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 84 | 0.450 |
Why?
|
| Continental Population Groups | 1 | 2017 | 283 | 0.450 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 54 | 0.390 |
Why?
|
| Age Factors | 4 | 2024 | 874 | 0.370 |
Why?
|
| Sex Factors | 3 | 2024 | 599 | 0.360 |
Why?
|
| Phenotype | 3 | 2026 | 154 | 0.330 |
Why?
|
| Pandemics | 2 | 2023 | 295 | 0.320 |
Why?
|
| Antihypertensive Agents | 2 | 2024 | 163 | 0.320 |
Why?
|
| Adolescent | 6 | 2026 | 3625 | 0.320 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 53 | 0.310 |
Why?
|
| California | 4 | 2026 | 2433 | 0.310 |
Why?
|
| Cohort Studies | 5 | 2023 | 2502 | 0.290 |
Why?
|
| Young Adult | 5 | 2026 | 2538 | 0.280 |
Why?
|
| Prevalence | 3 | 2023 | 830 | 0.280 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 1295 | 0.270 |
Why?
|
| Cardiac Rehabilitation | 1 | 2025 | 6 | 0.240 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2026 | 57 | 0.230 |
Why?
|
| Home Care Services | 1 | 2025 | 34 | 0.230 |
Why?
|
| Medicare | 3 | 2024 | 197 | 0.230 |
Why?
|
| Interviews as Topic | 1 | 2025 | 324 | 0.210 |
Why?
|
| Proportional Hazards Models | 2 | 2026 | 702 | 0.210 |
Why?
|
| Quality of Health Care | 1 | 2026 | 260 | 0.200 |
Why?
|
| Life Style | 1 | 2025 | 321 | 0.200 |
Why?
|
| Prospective Studies | 4 | 2023 | 1251 | 0.200 |
Why?
|
| Residence Characteristics | 1 | 2025 | 256 | 0.200 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2023 | 19 | 0.200 |
Why?
|
| Disease Progression | 1 | 2024 | 266 | 0.200 |
Why?
|
| Diabetic Retinopathy | 1 | 2023 | 17 | 0.200 |
Why?
|
| Retinal Diseases | 1 | 2023 | 17 | 0.200 |
Why?
|
| Telemedicine | 1 | 2026 | 196 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2026 | 452 | 0.180 |
Why?
|
| Acute Disease | 1 | 2022 | 147 | 0.170 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 1296 | 0.170 |
Why?
|
| Time Factors | 3 | 2020 | 1038 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 15 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2026 | 719 | 0.160 |
Why?
|
| Child | 2 | 2026 | 2485 | 0.160 |
Why?
|
| Prognosis | 2 | 2020 | 609 | 0.150 |
Why?
|
| Rosuvastatin Calcium | 1 | 2019 | 4 | 0.150 |
Why?
|
| Inpatients | 1 | 2020 | 78 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 47 | 0.150 |
Why?
|
| Outpatients | 1 | 2020 | 103 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2020 | 151 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2019 | 119 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2026 | 1093 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1157 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 158 | 0.140 |
Why?
|
| HIV Infections | 1 | 2023 | 584 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 48 | 0.130 |
Why?
|
| Law Enforcement | 1 | 2017 | 2 | 0.130 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 15 | 0.130 |
Why?
|
| Biomarkers | 1 | 2017 | 302 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 143 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 384 | 0.120 |
Why?
|
| Comorbidity | 2 | 2020 | 552 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 363 | 0.070 |
Why?
|
| Patient Discharge | 2 | 2019 | 154 | 0.060 |
Why?
|
| Hawaii | 1 | 2026 | 62 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2026 | 302 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2026 | 237 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2026 | 135 | 0.060 |
Why?
|
| Length of Stay | 1 | 2026 | 182 | 0.060 |
Why?
|
| Fumarates | 1 | 2023 | 4 | 0.050 |
Why?
|
| Adenine | 1 | 2023 | 7 | 0.050 |
Why?
|
| Tenofovir | 1 | 2023 | 14 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 603 | 0.050 |
Why?
|
| Registries | 1 | 2026 | 475 | 0.050 |
Why?
|
| Retreatment | 1 | 2020 | 2 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 38 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 66 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 228 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 248 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 686 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 470 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 304 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 446 | 0.030 |
Why?
|
| Contrast Sensitivity | 1 | 2017 | 1 | 0.030 |
Why?
|
| Automobile Driving | 1 | 2017 | 10 | 0.030 |
Why?
|
| Alabama | 1 | 2017 | 23 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 122 | 0.030 |
Why?
|
| Independent Living | 1 | 2017 | 24 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 348 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2017 | 1161 | 0.030 |
Why?
|
Concepts
(131)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->